<DOC>
	<DOCNO>NCT02403284</DOCNO>
	<brief_summary>In research study , investigator test effect approve medication diabetes , Liraglutide , reduce insulin resistance develop eat diet high saturate fat .</brief_summary>
	<brief_title>The Effect Liraglutide Dietary Lipid Induced Insulin Resistance Humans</brief_title>
	<detailed_description>The specific aim study determine ability subacute liraglutide administration protect dietary lipid induce peripheral insulin resistance non-diabetic subject normal glucose tolerance . Recent data laboratory others suggest high fat meal , enrich saturate fatty acid ( SFA ) particular , unique profound ability induce rapid ( ≤ 24 hr ) profound onset insulin resistance human . This presumably mediate part delivery lipids lipid product generate postprandial lipolysis non-adipose tissue . This unique model therefore provide excellent platform test agent ability inhibit dietary induced insulin resistance . As others demonstrate ability GLP-1 receptor agonist markedly suppress postprandial lipid elevation modify lipid metabolism , hypothesize liraglutide may effective agent inhibit development dietary induce insulin resistance .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Age 4075 year old 2 . Body mass index ( BMI ) 22 35 kg/m2 3 . Normal glucose tolerance determine fast blood glucose ( &lt; 100 mg/dl ) 75 gm glucose load ( 2 hr glucose &lt; 140 mg/dl ) 4 . Fasting triglyceride level ≥ 75 mg/dl &lt; 500 mg/dl 1 . Type 1 2 diabetes mellitus hemoglobin A1c value &gt; 6.5 mg/dl 2 . Any diabetes medication past month , thiazolidinedione medication prior 3 month prior regular use insulin 3 . Lactose intolerance avoidance dairy product 4 . Creatinine &gt; 2.0 mg/dl laboratory evidence active disease , include hepatic enzyme elevation ( AST ALT ) &gt; 2.5 x normal anemia ( Hct &lt; 35 ) 5 . Known 'Nonalcoholic Fatty Liver Disease ' 6 . Malabsorption fat nutrient , severe lactose intolerance significant gastrointestinal pancreatic problem ( include history acute chronic pancreatitis ) . 7 . Recent history nausea vomit 8 . Acute bacterial viral illness evidence active infection past 4 week 9 . Prior cardiovascular event , stable unstable angina major illness past 6 month 10 . Current regular use antiinflammatory medication antioxidant excess standard daily multivitamin , include thecounter medication high dose salicylate ( &gt; 1 gm/ day ) 11 . Subjects receive lipid lower medication must stable dose least 6 week prior participation . 12 . Personal family history medullary thyroid carcinoma patient multiple endocrine neoplasia 2 13 . Ethanol consumption 4 oz day 14 . Pregnancy , lack appropriate contraceptive use premenopausal woman ( extremely rare older predominately male population ) 15 . Poorly control hypertension , systolic blood pressure ( SBP ) &gt; 150 diastolic blood pressure ( DBP ) &gt; 90 2 occasion screen visit . Subjects receive blood pressure medication stable dose least 6 week prior participation . 16 . BMI &lt; 22 &gt; 35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>insulin resistance</keyword>
	<keyword>lipid metabolism</keyword>
	<keyword>glucose metabolism</keyword>
	<keyword>high fat diet</keyword>
</DOC>